Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии ФУВ РГМУ, Москва
• пациент регулярно принимает меньшее количество препарата, чем ему было прописано; • пациент принимает препарат нерегулярно («on-and-off» dosing). Например, прием препарата так, как было предписано, периодическое прекращение приема препарата, прием меньшего количества, чем предписано; • пациент прекращает прием препарата на продолжительный период времени (перерыв в терапии [gap in treatment]).
• удобство процесса лечения (удобные терапевтические схемы и препараты с хорошей переносимостью), • эффективность применяемых препаратов, • осознанный поход к процессу терапии, • в целом – удовлетворенность процессом и достигаемыми результатами терапии.
• понимание причин несоблюдения терапии пациентом, • наличие качественных знаний о существующих современных способах терапии и подбора лечения.
Список исп. литературыСкрыть список 1. Valenstein M et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiat 2006; 67 (10): 1542–50. 2. Olfson M et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiat Serv 2000; 51 (2): 216–22. 3. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002; 54 (3): 253–64. 4. Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiat 2002; 17 (3): 148–54. 5. Lindenmayer JP et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiat 2009; 70 (7): 990–6. 6. Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiat 2001; 62 (5): 394–9; quiz 400-1. 7. Lieberman JA et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209–23. 8. Shajahan P et al. Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol 2008; 22 (7): 778–83. 9. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66 (1): 51–7. 10. Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence 2009; 3: 345–55. 11. Dolder CR et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiat 2002; 159 (1): 103–8. 12. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiat Serv 2001; 52 (6): 805–11. 13. Al-Zakwani IS et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003; 19 (7): 619–26. 14. Menzin J et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiat Serv 2003; 54 (5): 719–23. 15. Mojtabai R et al. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr Bull 2003; 29 (3): 519–30. 16. Opolka JL et al. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003; 37 (5): 625–30. 17. Ascher-Svanum H et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2008; 2: 67–77. 18. Diaz E et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiat 2004; 65 (3): 354–60. 19. Gilmer TP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiat 2004; 161 (4): 692–9. 20. Valenstein M et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30 (2): 255–64. 21. Velligan DI et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiat Serv 2007; 58 (9): 1187–92. 22. Velligan DI et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006; 32 (4): 724–42. 23. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiat Clin North Am 2007; 30 (3): 437–52. 24. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiat 2002; 63 (12): 1121–8. 25. Weiden P et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiat Serv 1995; 46 (10): 1049–54. 26. Law MR et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiat 2008; 69 (1): 47–53. 27. Weiden PJ et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiat Serv 2004; 55 (8): 886–91. 28. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiat 2008; 8: 32. 29. Alia-Klein N et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav 2007; 33 (1): 86–96. 30. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12 (5): 423–4. 31. Ascher-Svanum H et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiat 2006; 67 (3): 453–60. 32. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr, 2007; 12 (10 Suppl. 17): 21–6. 33. Robinson DG et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31 (3): 705–22. 34. Robinson D et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiat 1999; 56 (3): 241–7. 35. Kane JM et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiat 2003; 64 (Suppl. 12): 5–19. 36. Fenton WS, Schooler NR. Evidence-based psychosocial treatment for schizophrenia. Schizophr Bull 2000; 26 (1): 1–3. 37. Dolder CR et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003; 23 (4): 389–99. 38. Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007; 67 (11): 1541–66. 39. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18 (2): 113–32. 40. Davis JM, Barter JT, Kane JM. Antipsychotic drugs, in Comprehensive textbook of psychiatry, R.Cancro et al., Editors. 1989, Williams & Wilkins: Baltimore. 41. Olivares JM et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiat 2009; 24 (5): 287–96. 42. Kim B et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiat 2008; 32 (5): 1231–5.